Sugi Predict

Sugi Predict / Targets / TNNI3

TNNI3

Troponin I, cardiac muscle (Cardiac troponin · P19429 · TNNI3 on Sugi Atlas →

12,119 patent compounds predicted against TNNI3, 9,056 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2058443 SCHEMBL2058443 0.54 3/20
SCHEMBL2058445 SCHEMBL2058445 0.54 3/20
SCHEMBL1959899 SCHEMBL1959899 0.51 3/20
SCHEMBL1959900 SCHEMBL1959900 0.51 3/20
Sennoside A Sennoside A (SCHEMBL440792) 1.00 2/20
Sennoside B Sennoside B (SCHEMBL441194) 1.00 2/20
SCHEMBL722959 SCHEMBL722959 0.57 2/20
SCHEMBL940116 SCHEMBL940116 0.56 2/20
SCHEMBL1706253 SCHEMBL1706253 0.56 2/20
SCHEMBL1599043 SCHEMBL1599043 0.56 2/20
SCHEMBL941002 SCHEMBL941002 0.53 2/20
Aloin Aloin (SCHEMBL181616) 0.52 2/20
SCHEMBL1710516 SCHEMBL1710516 0.51 2/20
SCHEMBL244406 SCHEMBL244406 0.51 2/20
SCHEMBL1894380 SCHEMBL1894380 0.51 2/20
SCHEMBL939398 SCHEMBL939398 0.50 2/20
SCHEMBL1348301 SCHEMBL1348301 0.48 2/20
SCHEMBL1348304 SCHEMBL1348304 0.48 2/20
SCHEMBL814860 SCHEMBL814860 0.46 2/20
SCHEMBL814861 SCHEMBL814861 0.46 2/20

Clinical trials — most relevant to TNNI3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Acute Chest Pain Treatment and Evaluation (ACTION) Study PHASE4COMPLETED
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children PHASE3COMPLETED
Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics PHASE1COMPLETED
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings nanUNKNOWN
A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC). nanSUSPENDED
Hs-cTn - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women nanACTIVE_NOT_RECRUITING
SpinChip Hs-cTnI Clinical Diagnostic Performance nanCOMPLETED
SpinChip Hs-cTnI Sample Type Validation nanCOMPLETED
SpinChip Hs-cTnI Determination of the 99th Percentile URL nanCOMPLETED
Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis nanCOMPLETED
Preoperative BNP: Epidemiological Patterns, Management Strategies and Cost Analysis of Care nanCOMPLETED
SpinChip Hs-cTnI Multisite Precision nanCOMPLETED
Cardiac Injury With Convulsive Status Epilepticus nanUNKNOWN
COronary Microcirculation and Troponin Elevation in Septic Shock nanCOMPLETED
Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease nanACTIVE_NOT_RECRUITING
Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes nanCOMPLETED
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases nanCOMPLETED
Rheumatoid Arthritis Disease Activity and Sub Clinical Atherosclerosis nanCOMPLETED
ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study nanCOMPLETED
Risk Markers in the Acute Coronary Syndromes nanCOMPLETED
Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine nanUNKNOWN
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19 nanCOMPLETED
Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms nanUNKNOWN
Sleep Disordered Breathing in Acute Congestive Heart Failure nanCOMPLETED
TROPOnin FRAGMentation in Myocardial Injury Study nanRECRUITING
Out-of-hospital Cardiac Arrest (OHCA) Biomarkers nanCOMPLETED
Heart and Skeletal Muscle Problems in Neuroacanthocytosis nanCOMPLETED
Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin nanCOMPLETED
Observational Study on Cardiac Biomarkers Testing in Patients with Muscular Dystrophy Cardiomyopathy nanCOMPLETED
Hypersensitive Troponin Performance to Identify Syncope at Risk of Serious Adverse Events in the Short Term nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNNI3 binder may also engage these)

ProteinNameSimilarity
Q8MKD5 — 1.000 Q8MKD5 →
P08057 — 1.000 P08057 →
Q863B6 — 1.000 Q863B6 →
Q5PYI0 — 1.000 Q5PYI0 →
P02646 — 0.997 P02646 →
P23693 — 0.996 P23693 →
P48787 — 0.992 P48787 →
P02645 — 0.984 P02645 →
P68247 — 0.981 P68247 →
P68246 — 0.981 P68246 →
P50754 — 0.980 P50754 →
P19237 — 0.979 P19237 →
P27672 — 0.975 P27672 →
P09741 — 0.975 P09741 →
Q7TNB2 — 0.975 Q7TNB2 →
P50753 — 0.974 P50753 →
Q75ZZ6 — 0.974 Q75ZZ6 →
P13805 — 0.974 P13805 →
P50751 — 0.973 P50751 →
P02642 — 0.972 P02642 →
Q8MKI3 — 0.972 Q8MKI3 →
P27673 — 0.972 P27673 →
Q8R344 — 0.971 Q8R344 →
Q9BUP0 — 0.971 Q9BUP0 →
P12620 — 0.971 P12620 →
P19351 — 0.971 P19351 →
Q8MKH6 — 0.971 Q8MKH6 →
Q9D4J1 — 0.970 Q9D4J1 →
P02641 — 0.970 P02641 →
Q9D8Y0 — 0.970 Q9D8Y0 →